Behavioural interventions for smoking cessation: A meta-analysis of randomized controlled trials

Division of Cardiology and Clinical Epidemiology, Jewish General Hospital/McGill University, 3755 Côte Ste-Catherine Road, Suite A-118, Montreal, Quebec, Canada.
European Heart Journal (Impact Factor: 15.2). 03/2009; 30(6):718-30. DOI: 10.1093/eurheartj/ehn552
Source: PubMed


Widely varying estimates of treatment effects have been reported in randomized controlled trials (RCTs) investigating the efficacy of behavioural interventions for smoking cessation. Previous meta-analyses investigating behavioural interventions have important limitations and do not include recently published RCTs. We undertook a meta-analysis of RCTs to synthesize the treatment effects of four behavioural interventions, including minimal clinical intervention (brief advice from a healthcare worker), and intensive interventions, including individual, group, and telephone counselling.
We searched the CDC Tobacco Information and Prevention, Cochrane Library, EMBASE, Medline, and PsycINFO databases. We included only RCTs that reported biochemically validated smoking cessation outcomes at 6 and/or 12 months after the target quit date. Outcomes were aggregated using hierarchical Bayesian random-effects models. We identified 50 RCTs, which randomized n = 26 927 patients (minimal clinical intervention: 9 RCTs, n = 6456; individual counselling: 23 RCTs, n = 8646; group counselling: 12 RCTs, n = 3600; telephone counselling: 10 RCTs, n = 8225). The estimated mean treatment effects were minimal clinical intervention [odds ratio (OR) 1.50, 95% credible interval (CrI) 0.84-2.78], individual counselling (OR 1.49, 95% CrI 1.08-2.07), group counselling (OR 1.76, 95% CrI 1.11-2.93), and telephone counselling (OR 1.58, 95% CrI 1.15-2.29).
Intensive behavioural interventions result in substantial increases in smoking abstinence compared with control. Although minimal clinical intervention may increase smoking abstinence, there is insufficient evidence to draw strong conclusions regarding its efficacy.

Download full-text


Available from: Robert O Pihl, Dec 11, 2015
  • Source
    • "These results should be interpreted with caution, as researchers and participants were not blind to drug treatment conditions, and no control group was employed. However, it is noteworthy that the most successful current treatments for smoking cessation generally show far less efficacy, with typical abstinence rates below 35% at 6 months [23] [24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Psilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, attitudes, and values, and increases in the personality domain of openness. In an open-label pilot-study of psilocybin-facilitated smoking addiction treatment, 15 smokers received 2 or 3 doses of psilocybin in the context of cognitive behavioral therapy (CBT) for smoking cessation. Twelve of 15 participants (80%) demonstrated biologically verified smoking abstinence at 6-month follow-up. Participants who were abstinent at 6 months (n=12) were compared to participants still smoking at 6 months (n=3) on measures of subjective effects of psilocybin. Abstainers scored significantly higher on a measure of psilocybin-occasioned mystical experience. No significant differences in general intensity of drug effects were found between groups, suggesting that mystical-type subjective effects, rather than overall intensity of drug effects, were responsible for smoking cessation. Nine of 15 participants (60%) met criteria for "complete" mystical experience. Smoking cessation outcomes were significantly correlated with measures of mystical experience on session days, as well as retrospective ratings of personal meaning and spiritual significance of psilocybin sessions. These results suggest a mediating role of mystical experience in psychedelic-facilitated addiction treatment.
    Full-text · Article · Jan 2015 · Current Drug Abuse Reviews
  • Source
    • "The use of interventions for modification of health-related behaviors is advocated in the search for smoking cessation [12]. A meta-analysis has demonstrated the efficacy of intensive behavioral interventions in encouraging smoking cessation, with odds ratios (ORs) of 1.49 (95%CI 1.08 -2.07) for individual counseling, 1.76 (95%CI 1.11 -2.93) for group counseling, and 1.58 (95%CI 1.15 -2.29) for telephone counseling; all were associated with superior rates of smoking cessation as compared with a control group [13]. Another meta-analysis found that nurse-led interventions were significantly more effective in encouraging smoking cessation (OR 1.43, 95%CI 1.24 -1.66) than a control group. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The number of deaths associated with cardiovascular events remains constant in many countries due to new therapeutic approaches for prevention and treatment of atherosclerosis. This condi-tion is widely attributable to unhealthy outcomes in its association with risk factors such as smoking and sedentary behavior. Risk factors play a significant role in the progression of coro-nary artery disease. We conducted a review of the literature with the purpose of identifying pri-mary risk factors for coronary disease, lifestyle change interventions, and expectations for a re-duction in cardiovascular events on the basis of evidence-based health education strategies. In addition, we sought to contextualize this review so that nurses are trained to use these findings in their practice at different levels of care.
    Full-text · Article · Apr 2014 · Health
    • "Currently, however, there is a growing trend in physicians’ indifference or scepticism towards the efficacy of smoking cessation programs [19]. Moreover, the use of pharmaceutical cessation aids [20] and behavioural support [21] have led to limited success in cessation, and it has been argued that the majority of current smokers will continue to smoke without acceptable safer alternatives [22]. Therefore, the case for an effective THR strategy is legitimate. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Smokers of any age can reap substantial health benefits by quitting. In fact, no other single public health effort is likely to achieve a benefit comparable to large-scale smoking cessation. Surveys document that most smokers would like to quit, and many have made repeated efforts to do so. However, conventional smoking cessation approaches require nicotine addicted smokers to abstain from tobacco and nicotine entirely. Many smokers are unable -- or at least unwilling -- to achieve this goal, and so they continue smoking in the face of impending adverse health consequences. In effect, the status quo in smoking cessation presents smokers with just two unpleasant alternatives: quit or suffer the harmful effects of continuing smoking. But, there is a third choice for smokers: tobacco harm reduction. It involves the use of alternative sources of nicotine, including modern smokeless tobacco products like snus and the electronic cigarette (E-cig), or even pharmaceutical nicotine products, as a replacement for smoking. E-cigs might be the most promising product for tobacco harm reduction to date, because, besides delivering nicotine vapour without the combustion products that are responsible for nearly all of smoking's damaging effect, they also replace some of the rituals associated with smoking behaviour. Thus it is likely that smokers who switch to E-cigs will achieve large health gains. The focus of this article is on the health effects of using an E-cig, with consideration given to the acceptability, safety and effectiveness of this product as a long-term substitute for smoking.
    No preview · Article · Oct 2013 · Harm Reduction Journal
Show more